ArticleBiochemistry and biophysics reports2025
Clinical application study of a novel fully automatic erythrocyte osmotic fragility analysis system.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Existing erythrocyte osmotic fragility test (EFT) methods are constrained by subjectivity, poor reproducibility, and lack of standardization, limiting their clinical utility in thalassemia screening. This study evaluates the RA-800 Plus, a novel fully automated EFT analyzer, as a scalable tool for thalassemia screening and aims to establish reference intervals for healthy individuals. By addressing the key limitations of manual EFTs, this work seeks to promote methodological innovation and enable standardized, high-throughput screening in diverse clinical settings. Methods: EFTs were performed on 273 healthy adults via an RA-800 Plus analyzer. The light scattering turbidity method was employed to establish a reference interval within the normal range. The neonatal samples were tested in the same way to determine the newborn-specific range. Moreover, 97 samples underwent dual tests of RA-800 Plus analysis and the gold standard (genetic testing) to evaluate the diagnostic performance. A total of 103 pairs of samples were detected and compared via an automated system and the traditional manual direct colorimetric method, further verifying the consistency of the two methods. The effects of anticoagulant type, sample storage, and rewarming were also investigated. Results: RA-800 Plus demonstrated high reliability, with minimal influence from anticoagulants and sample handling conditions. The analyzer showed an 84 % detection rate for β-thalassemia, indicating superior effectiveness for β-thalassemia screening. The test results were consistent with the manual method (Kappa ≥0.6). ROC curve analysis confirmed the suitability of both methods for thalassemia screening, with AUCs of 0.91 for β-thalassemia and 0.72 for α-thalassemia. Conclusions: The RA-800 Plus offers a fully automated, reliable, and clinically viable alternative for thalassemia screening, particularly for β-thalassemia. Its stability, accuracy, and ease of use make it a valuable tool for improving thalassemia diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.